Oragenics, Inc. (OGEN) News
Track canonical SquawkNews coverage tagged to OGEN, Oragenics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 7 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Oragenics discloses failure to satisfy continued listing rule
Oragenics disclosed a failure to satisfy a continued listing rule or standard.
EQUITY | Aug 28, 2026, 09:14 PM UTC
L
Oragenics review continues; plans for an IND by end-2026
Oragenics says it is reviewing certain items and remains focused on submitting an Investigational New Drug Application by the end of 2026.
EQUITY | Aug 28, 2026, 08:31 PM UTC
L
OGEN - Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
OGEN - Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
EQUITY | Aug 28, 2026, 08:31 PM UTC
M
Oragenics receives NYSE American deficiency notice
Oragenics (OGEN) received a deficiency letter from NYSE American LLC stating it is not in compliance with continued listing standards.
EQUITY | Aug 28, 2026, 08:31 PM UTC
L
Oragenics receives FDA responses on Type B meeting briefing
Oragenics received responses from the FDA related to its Type B meeting request briefing package submitted in July.
REGULATION | Aug 28, 2026, 08:31 PM UTC
L
Oragenics advances ONP-002 through Phase IIa feasibility trial in Australia
Oragenics says it is continuing to advance ONP-002, its lead intranasal mTBI candidate, through a Phase IIa feasibility trial in Australia.
EQUITY | Aug 28, 2026, 08:31 PM UTC
H
Oragenics Says All Three Australian Concussion Trial Sites Enrolling Patients
() -- Oragenics (OGEN) said Tuesday that the three sites in its Australian phase 2a clinical trial of ONP-002 to treat mild traumatic brain injury, or concussion, are now active and enrolling patients. The biotech firm s
EARNINGS | Jul 07, 2026, 01:07 PM UTC